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Abstract
Objective—To evaluate whether 17-alpha hydroxyprogesterone caproate (17-OHP) reduces
preterm birth (PTB) in nulliparous women with a midtrimester cervical length (CL) less than 30
mm.
Study Design—In this multicenter randomized controlled trial, nulliparous women with a
singleton gestation between 16 and 22 3/7 weeks with an endovaginal CL < 30 mm (<10th
percentile in this population) were randomized to weekly intramuscular 17-OHP (250 mg) or
placebo through 36 weeks. The primary outcome was PTB < 37 weeks.
Results—The frequency of PTB did not differ between the 17-OHP (N = 327) and placebo (N =
330) groups (25.1% vs. 24.2%; relative risk (RR) 1.03, 95% confidence interval (CI), 0.79 – 1.35).
There also was no difference in the composite adverse neonatal outcome (7.0% vs. 9.1%: RR 0.77,
95% CI 0.46 – 1.30).
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Conclusion—Weekly 17-OHP does not reduce the frequency of PTB in nulliparous women with
a midtrimester CL < 30 mm. (ClinicalTrials.gov number, NCT00439374).
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Preterm birth (PTB) remains a major cause of morbidity and mortality worldwide. Not only
is it responsible for approximately 50 percent of childhood blindness and one-third of
cerebral palsy, but it increasingly has been implicated in adult morbidities, such as
cardiovascular disease.1,2 Correspondingly, PTB reduction has been a prominent public
health goal and a focus of perinatal research.
Progestogens, administered intramuscularly or vaginally, have been demonstrated to reduce
the frequency of recurrent preterm birth.3,4 Although progestogens in this circumstance have
been demonstrated to be efficacious, PTB epidemiology is such that their use for this
indication will not markedly reduce the population’s frequency of PTB.5 Thus, investigators
have evaluated whether progestogens also can reduce PTB in other at-risk groups. Although
progestogen treatment does not reduce PTB in women with multiple gestations,6–8 it has
been shown in two randomized trials to reduce PTB in women with a short cervix.9,10 The
inclusion criterion for cervical length (CL) was less than 15mm in one trial, and 10–20mm
in the other trial.
However, because the frequencies of a CL less than 15 mm or of 10–20 mm are
approximately 1% and 2%, respectively, the restriction of progestogen to such women will
not result in a substantial reduction in the overall PTB frequency and will leave many
women who might benefit from its use untreated. In this study, we examined whether the
use of 17-alpha hydroxyprogesterone caproate (17-OHP) administered to nulliparous women
with a CL less than 30 mm (i.e., the 10th percentile at 16–22 weeks of gestation) would
reduce PTB prior to 37 weeks.
Methods
From April 2007 through May 2011, the fourteen centers of the Maternal-Fetal Medicine
Units Network of the Eunice Kennedy Shriver National Institute of Child Health and Human
Development participated in this randomized double-blind placebo-controlled trial. The
study was approved by the institutional review board at each clinical site and at the data
coordinating center.
Women were eligible for participation if they were nulliparous with a viable singleton
gestation and had a CL less than 30 mm between 16 weeks 0 days and 22 weeks 3 days.
This gestational age range was chosen because it is during this period that women typically
receive a sonographic examination for fetal evaluation. A woman was defined as nulliparous
if she had no prior pregnancy that progressed beyond 19 weeks 6 days. Women were
excluded from participation if they had undergone a selective fetal reduction to a singleton
gestation; had sonographic evidence of an additional fetal pole/embryo at 12 weeks of
gestation or later; had received progestogen treatment after 14 weeks 6 days; had
experienced vaginal bleeding heavier than spotting after 15 weeks 6 days; had amniotic
membranes prolapsing beyond the external os; had premature rupture of membranes; had a
known major fetal anomaly or aneuploidy; had a current or planned cervical cerclage; had a
known Mullerian abnormality; had a contraindication to intramuscular injections; had
maternal medical conditions that increase the probability of preterm delivery (e.g.
hypertension); had prior cervical surgery (i.e., cold knife conization, laser vaporization or
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loop electrosurgical excision procedure; or were planned to have an indicated preterm
delivery.
For women who conceived spontaneously, the duration of gestation at the time of
randomization was determined according to a previously described algorithm on the basis of
the last menstrual period and the results of ultrasonography.11 For women who conceived by
in vitro fertilization, the duration of gestation was calculated on the basis of the date of
embryo transfer and the age of the embryo when transferred.
CL was measured endovaginally by trained and certified sonographers. Sonographer training
consisted of a didactic program based on the method described by Iams et al. for
endovaginal CL measurement.12 To become certified, a sonographer submitted three
cervical images from each of five separate women, designating which of the three images
per patient was the best image with the shortest measurement, and whether a funnel and/or
debris (defined as echogenic material adjacent to the cervix within the amniotic cavity) were
present. The images were reviewed centrally by an expert (JDI). Study personnel were
certified only when the images of at least four of the five studies submitted were considered
acceptable. Once certified, sonographers performed CL screening of women potentially
eligible for the randomized trial in a standard fashion, by obtaining three cervical length
images and measuring each cervix along the line of the cervical canal made by the interface
of the mucosal surfaces, with calipers placed at the external and internal os. The shortest
measurement was recorded and was the basis for eligibility for the trial.
Eligible women were offered participation into the randomized, double-blind, placebo-
controlled trial. Women who signed informed consent received an intramuscular
“compliance” injection of the placebo (1 ml inert oil), and were asked to return at least three
days later, at which time randomization occurred. If a woman did not return for a
randomization visit before 23 weeks 0 days of gestation, she was excluded from
participation in the trial. Additionally, before randomization, all women were required to
have a sonographic examination to exclude fetal anomalies and to estimate gestational age if
no previous dating ultrasound had been performed. Women who met inclusion criteria and
returned at the appropriate time after the “compliance” injection were assigned in a 1:1 ratio
to receive identically appearing active (250 mg 17-OHP) or placebo (castor oil)
intramuscular injections prepared according to CGMP guidelines by a research pharmacy
(Eminent Services, Frederick, MD). The simple urn method of randomization, with
stratification according to clinical center, was used by the data coordinating center to create
the computer-generated randomization sequence.13 The active and placebo study
medications were distributed according to this randomization sequence. The study was
double masked; neither the patient nor medical staff (including research and clinical
personnel) was aware of the treatment assignment. After randomization, participants
received weekly intramuscular injections of 250 mg 17-OHP or placebo given by a study
nurse, until 36 weeks 6 days of gestation or delivery, whichever occurred first. Compliance
with the intervention was determined by the proportion of protocol-specified injections (one
injection every 5–9 days from randomization to 36 weeks 6 days or delivery, whichever
occurred first) that was received prior to delivery.
At each study visit, participants were asked whether they had experienced adverse
symptoms since the last injection. In addition, they were asked whether they had consulted a
physician for preterm labor symptoms, had undergone any medical procedures, or had been
given any corticosteroids or tocolytic medications since their last visit. Participants also
were queried about any activity restrictions that had been prescribed by their health
provider. Prenatal, delivery, newborn, and postpartum records were abstracted by study
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personnel after delivery. Participating women and their infants were followed until hospital
discharge.
PTB was defined as delivery prior to 37 weeks 0 days of gestation. Pre-specified secondary
outcomes included PTB prior to 35 weeks 0 days and prior to 32 weeks 0 days gestation, a
composite of serious adverse fetal or neonatal outcomes (i.e., respiratory distress syndrome,
bronchopulmonary dysplasia, early-onset sepsis, grade II or III necrotizing enterocolitis,
grade III or IV intraventricular hemorrhage, periventricular leukomalacia, grade III or IV
retinopathy of prematurity, or fetal or neonatal death), and selected individual maternal and
neonatal morbidities.
We estimated that 20 percent of the women in the placebo group would deliver before 37
weeks of gestation.12,14,15 Based on this estimate, a total sample size of 1000 women (500
in each group) was estimated to be sufficient to detect a reduction of 33 percent in the
frequency of preterm delivery before 37 weeks, under the assumptions of a type I error (two-
sided) of 5 percent and a power of at least 80 percent. This sample size also would yield
more than 90% power to detect the same effect size if the frequency in the placebo group
were as high as 25%. The analysis was performed according to the intention-to-treat
principle. Continuous variables were compared with the use of the Wilcoxon rank-sum test,
and categorical variables were compared with the use of the chi-square or Fisher’s exact test,
as appropriate. The proportion of women in each study group remaining pregnant was
compared using survival analysis with the log-rank test used to assess for the difference
between the survival curves. A priori subgroup analyses were planned for the primary
outcome with respect to the selected variables of gestational age at randomization (prior to
21 weeks 0 days of gestation versus at least 21 weeks 0 days of gestation), CL at screening
(less than 15 mm versus at least 15 mm), and the presence or absence of a cervical funnel at
screening. These analyses utilized Mantel-Haenszel stratification with the Breslow-Day test
to assess for homogeneity. All tests were two-tailed and P < 0.05 was used to define
statistical significance. Analyses were performed using SAS, version 9.2 (SAS Institute Inc.,
Cary, NC).
An independent data and safety monitoring committee (DSMC) monitored the trial. A group
sequential method was used to characterize the rate at which the type I error was spent; the
chosen function was the Lan-DeMets characterization of the O’Brien-Fleming boundary.16
At the 3rd interim analysis, conducted when outcome data were available for 591 patients
(59.1% percent of the planned sample), a conditional power analysis revealed that even if
recruitment continued to the final sample size of 1000 women, and the primary outcome
frequencies in the remaining women were as assumed for the alternative hypothesis (13.3%
in the 17-OHP arm and 20% in the placebo arm) the probability of showing a benefit was
extremely low (< 2.5%). Based on these data and the recommendation of the DSMC,
enrollment in the trial was halted on May 9th, 2011.
Results
A total of 15,435 women were screened, of whom 1,588 (10.3%) had a CL less than 30 mm.
At the time the study was halted, 657 women had been randomized. Outcome data were
available for all randomized participants and their neonates (Figure 1). Baseline
characteristics of the two study groups were largely similar, although women randomized to
17-OHP treatment were slightly older (Table 1). The mean compliance rate was 88.8% in
the 17-OHP group and 89.1% in the placebo group (P = 0.89). Seven women (1.1%) also
were prescribed vaginal progesterone by their health care provider (2 in the 17-OHP group
and 5 in the placebo group, P = 0.45).
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The frequency of the primary outcome did not differ significantly between groups (Table 2).
Delivery prior to 37 weeks of gestation occurred in 25.1% of women in the 17-OHP group
and 24.2% of women in the placebo group (relative risk (RR), 1.03; 95% confidence interval
(CI), 0.79 to 1.35). The proportion of spontaneous and medically-indicated deliveries was
similar between the groups (Table 2). The proportion of births prior to 35 weeks and prior to
32 weeks also was similar between the groups, as were the survival curves from
randomization to delivery (P = 0.55) (Figure 2). The median gestational ages at delivery
were similar as well (38.9 weeks, interquartile range 36.9 – 40.0 in the 17-OHP group vs.
38.9, interquartile range 37.1–40.0 in the placebo group; P = 0.93). There were no
differences in other selected maternal outcomes. A majority of women in both groups noted
side effects from the injections, the majority of which were related to irritation at the
injection site.
Table 3 presents selected perinatal outcomes. There were no differences between groups in
the composite adverse perinatal outcome or in most individual outcomes. The exception was
that early-onset sepsis was less frequent in the 17-OHP group (0.9% versus 3.4%; RR 0.27,
95% CI 0.08 – 0.97). There were no differences between groups with regard to the
frequency of low birth weight, small-for-gestational-age birth weight, or admission to the
neonatal intensive care unit.
Planned subgroup analyses were performed to determine whether any interaction existed
between selected variables and treatment group (Table 4). Stratification based on gestational
age at randomization less than 21 weeks of gestation, CL less than 15 mm at screening, or
the presence of a funnel at screening did not reveal any interaction with treatment group.
Additional subgroup analyses, not defined a priori, were performed to examine the effect of
17-OHP on preterm birth < 37 weeks and < 34 weeks among women with a CL of 10–20
mm, as well on preterm birth < 34 weeks among women with a CL < 15mm (Table 5).
Stratification by these cervical lengths also failed to demonstrate any interaction with
treatment group.
Comment
In this randomized trial conducted among nulliparous women with singleton gestations and
midtrimester CLs less than 30 mm, weekly intramuscular injections of 250 mg 17-OHP
neither altered the frequency of PTB prior to 37 weeks nor had a discernable effect on PTB
at lower gestational age thresholds, maternal outcomes, or most neonatal complications.
While there was a lower frequency of early-onset sepsis among the neonates of mothers
exposed to 17-OHP, the lack of difference between the two groups in either gestational age
at delivery or other neonatal outcomes suggests that this may be a chance finding.
Unlike women with a prior PTB, nulliparous women with a singleton gestation have no risk
factor that can be derived from their obstetric history that allows for targeted preterm birth
prevention. A short CL is useful in risk stratification for nulliparous women, as it has been
shown in this population to have the greatest population attributable risk associated with
PTB.14 A threshold of 30 mm during the gestational age range that we studied not only
would allow approximately 10% of nulliparous women to be eligible for treatment aimed at
PTB prevention but would also identify women at clinically significant risk of PTB.14,15,17
Indeed, the probability of PTB in the present cohort was 25%, a frequency similar to that
cited for a general population of women who have had a prior PTB.14 The primary outcome
of our study, PTB prior to 37 weeks gestation, was chosen given the recognition that
prevention of all PTBs, even those in the late preterm period between 34 weeks 0 days and
36 weeks 6 days, is desirable given the health and economic burden associated with these
births.18–20
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The results of this study contrast with the results of two prior randomized trials that have
shown that vaginal progesterone treatment reduces the frequency of PTB in women with a
short cervix. One potential explanation is that those trials enrolled women with notably
shorter cervical lengths (less than 15 mm and 10–20 mm) that are present in only 1% and
2% of women, respectively.9,10 The presence of a “short” cervix, defined according to a
population standard and not underlying pathophysiology, may not reflect a single
parturitional process that is uniformly amenable to progestogen therapy. Indeed, PTB is best
understood as a complex condition with multiple potential etiologies.21,22 Investigators of
prior trials have recognized this possibility; one reason that Hassan et al chose 10–20 mm
for progesterone treatment was their concern that women with a cervix less than 10 mm
“have a higher rate of intra-amniotic infection/inflammation” and would be “less likely to
benefit from progesterone administration than are patients with a longer cervix.”10 Although
the present study was unable to demonstrate benefit from 17-OHP at shorter cervical
lengths, it was underpowered to do so, and thus cannot be used to make conclusions about
progestogen treatment for women with such cervical lengths. Conversely, the current study
is the largest trial to date of women treated with a progestogen for a short cervix, the
substantial majority of whom had a CL greater than 20 mm. While one meta-analysis did
suggest that progesterone was effective for women with a CL up to 25 mm, more than 90%
of women in that analysis were from studies that restricted enrollment to women with a CL
≤ 20 mm, and all women with a CL > 20 mm had high-risk conditions, such as prior preterm
birth.23 Accordingly, in light of the negative findings, there is at present no evidence from
any randomized trial that progestogens benefits nulliparous women with a CL greater than
20 mm.
There are other possible reasons for the discrepant findings as well. Both Fonseca et al and
Hassan et al used vaginal progesterone, albeit different formulations.9,10 Although both 17-
OHP and vaginal progesterone have been shown to be efficacious at reducing recurrent
PTB, it is possible that a vaginally administered progesterone may be of particular benefit
for women with a short cervix. However, this possibility remains purely speculative, as 17-
OHP has not been evaluated in an adequately powered trial of women with a CL less than 20
mm, and vaginal progesterone has not been evaluated in an adequately powered trial of
women with singleton gestations and no prior preterm birth with a CL greater than 20mm.
Additional comparative effectiveness or placebo-controlled trials may provide further
insight. The previously published two trials also differed from the present study with regard
to their populations. These trials included women with other risk factors for PTB, including
multiple gestations, prior PTBs, and prior cervical surgeries. The present study, in contrast,
excluded women with such conditions, and focused instead on an otherwise low-risk
population of women who were nulliparous and had no other indication for either
progestogen treatment or PTB surveillance. Such differences in the study population also
may explain the different results.
The population that was selected should be generalizable to the general population of
nulliparous women with a singleton gestation. Women were enrolled from across the United
States in fourteen different centers, and were socioeconomically diverse. Approximately
10% had a CL less than the 10th percentile, as predicted from prior observational
studies.14,15,17 The frequency of PTB, moreover, was 24.7%, which similarly is consistent
with the frequency of PTB for nulliparous women with a cervix less than the 10th percentile
that has been cited in other studies.14,15
In summary, the results of our trial show no demonstrable benefit from the use of weekly
intramuscular 17-OHP to reduce the frequency of PTB in nulliparous women with a
midtrimester CL less than 30 mm. Further investigation is needed to determine whether 17-
OHP may benefit women with a CL below a lower percentile threshold, or whether other
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forms of progestogens provide benefit for women other than the 1–2% of the population
identified by the CL criteria used in prior trials.
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Flow diagram detailing patient enrollment
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Survival curve illustrating the proportion of participants remaining pregnant after
randomization.
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Maternal age at screening (years) 22.8 ± 5.3 21.6 ± 4.4
Pre-pregnancy body mass index (kg/m2)† 26.1 ± 6.9 25.4 ± 6.5
Race/ethnicity‡
   Non-Hispanic White 76 (23.2) 74 (22.4)
   Non-Hispanic Black 179 (54.7) 161 (48.8)
   Hispanic White 19 (5.8) 38 (11.5)
   Hispanic Black 2 (0.6) 0
   Asian 4 (1.2) 3 (0.9)
   Other 47 (14.4) 54 (16.4)
Prior pregnancy
   < 13 weeks of gestation 92 (28.1) 82 (24.8)
   13–19 weeks of gestation 13 (4.0) 10 (3.0)
Payment for obstetric care
   Uninsured/self-pay 17 (5.2) 30 (9.1)
   Private insurance 74 (22.6) 62 (18.8)
   Government-assisted insurance 236 (72.2) 238 (72.1)
Married or living with partner 125 (38.2) 110 (33.3)
Alcohol use during pregnancy 33 (10.1) 20 (6.1)
Smoking during pregnancy 48 (14.7) 62 (18.8)
Illicit substance use during pregnancy 15 (4.6) 24 (7.3)
Gestational age at randomization (weeks) 21.4 ± 1.2 21.3 ± 1.3
Cervical length at screening (mm) 23.9 ± 5.6 23.8 ± 5.7
Cervical length at screening < 15 mm 25 (7.6) 31 (9.4)
Cervical funnel present□ 88 (26.9) 69 (20.9)
Cervical funnel length (mm)□ 14.8 ± 8.0 16.7 ± 8.7
Debris present 39 (11.9) 39 (11.8)
Data are presented as mean ± standard deviation or n (%).
The only between-group difference that was significant was maternal age at screening (P = 0.003).
Percentages may not total 100 percent due to rounding.
†
Values were unavailable for 4 mothers in the 17-OHP group and 9 mothers in the placebo group.
‡
Race or ethnicity was self-reported.
□
Values were available for all mothers with a funnel present; 88 in the 17-OHP group and 69 in the placebo group.
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Table 2






Delivery < 37 weeks 82/327 (25.1) 80/330 (24.2) 1.03 (0.79 – 1.35)
   Spontaneous 54/327 (16.5) 55/330 (16.7) 0.99 (0.70 – 1.40)
   Medically indicated 27/327 (8.3) 25/330 (7.6) 1.09 (0.65 – 1.84)
   Fetal loss/abortion < 20 weeks 1/327 (0.3) 0/330 --
Gestational age at delivery (weeks) 37.6 ± 3.9 37.4 ± 4.3 P = 0.93
Preterm premature rupture of membranes 25/327 (7.6) 24/330 (7.3) 1.05 (0.61 – 1.80)
Delivery < 35 weeks 44/327 (13.5) 53/330 (16.1) 0.84 (0.58 – 1.21)
Delivery < 32 weeks 28/327 (8.6) 32/330 (9.7) 0.88 (0.54 – 1.43)
Delivery < 28 weeks 15/327 (4.6) 22/330 (6.7) 0.69 (0.36 – 1.30)
Hospital visit for preterm labor 145/327 (44.3) 151/330 (45.8) 0.97 (0.82 – 1.15)
Tocolytic therapy 35/321 (10.9) 42/325 (12.9) 0.84 (0.55 – 1.29)
Corticosteroid therapy 55/321 (17.1) 51/325 (15.7) 1.09 (0.77 – 1.55)
Cerclage placement 6/321 (1.9) 4/325 (1.2) 1.52 (0.43 – 5.33)
Gestational hypertension or preeclampsia 46/327 (14.1) 40/329 (12.2) 1.16 (0.78 – 1.72)
Gestational diabetes mellitus 15/327 (4.6) 13/330 (3.9) 1.16 (0.56 – 2.41)
Cholestasis 1/327 (0.3) 0/329 --
Placental abruption 11/327 (3.4) 15/328 (4.6) 0.74 (0.34 – 1.58)
Chorioamnionitis 29/327 (8.9) 20/328 (6.1) 1.45 (0.84 – 2.52)
Cesarean delivery 67/327 (20.5) 63/329 (19.1) 1.07 (0.79 – 1.46)
Side effects
   Any 223/326 (68.4) 220/328 (67.1) 1.02 (0.92 – 1.13)
   Injection site 217/326 (66.6) 209/328 (63.7) 1.04 (0.93 – 1.17)
   Urticaria 10/326 (3.1) 2/328 (0.6) 5.03 (1.11 – 22.78)
   Nausea 7/326 (2.1) 10/328 (3.0) 0.70 (0.27 – 1.83)
Data are presented as mean ± standard deviation or n/N (%)
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Composite adverse outcome 23/327 (7.0) 30/330 (9.1) 0.77 (0.46 – 1.30)
   Fetal death 4/327 (1.2) 1/330 (0.3) 4.04 (0.45 – 35.92)
   Neonatal death 6/327 (1.8) 8/330 (2.4) 0.76 (0.27 – 2.16)
   Respiratory distress syndrome 13/320 (4.1) 16/323 (5.0) 0.82 (0.40 – 1.68)
   Bronchopulmonary dysplasia 3/320 (0.9) 5/322 (1.6) 0.60 (0.15 – 2.51)
   Necrotizing enterocolitis, grade II or III 2/320 (0.6) 5/322 (1.6) 0.40 (0.08 – 2.06)
   Intraventricular hemorrhage, grade III or IV 2/320 (0.6) 1/322 (0.3) 2.01 (0.18 – 22.08)
   Periventricular leukomalacia 4/320 (1.3) 1/322 (0.3) 4.03 (0.45 – 35.81)
   Early-onset sepsis 3/320 (0.9) 11/322 (3.4) 0.27 (0.08 – 0.97)
   Retinopathy of prematurity, grade III or IV 1/320 (0.3) 3/322 (0.9) 0.34 (0.04 – 3.21)
Birth weight (g) 2855 ± 747 2824 ± 807 P = 0.82
   < 2500 g 72/323 (22.3) 75/328 (22.9) 0.97 (0.73 – 1.30)
   < 1500 g 23/323 (7.1) 29/328 (8.8) 0.81 (0.48 – 1.36)
Small-for-gestational age
   < 10th percentile 54/323 (16.7) 47/328 (14.3) 1.17 (0.81 – 1.67)
   < 3rd percentile 15/323 (4.6) 14/328 (4.3) 1.09 (0.53 – 2.22)
5-minute Apgar < 7 15/323 (4.6) 19/328 (5.8) 0.80 (0.41 – 1.55)
Major congenital anomaly 6/326 (1.8) 2/328 (0.6) 3.02 (0.61 – 14.85)
Patent ductus arteriosus 2/320 (0.6) 8/322 (2.5) 0.25 (0.05 – 1.18)
Seizures 1/320 (0.3) 2/322 (0.6) 0.50 (0.05 – 5.52)
NICU admission 63/322 (19.6) 69/329 (21.0) 0.93 (0.69 – 1.27)
Length of NICU stay 17 (6.0 – 43.0) 15.5 (6.0 – 57.5) P = 0.61
Data are presented as mean ± standard deviation, n/N (%), or median (interquartile range)
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   < 21 weeks 21/104 (20.2) 26/101 (25.7) 0.78 (0.47 – 1.30)
   ≥21 weeks 61/223 (27.4) 54/229 (23.6) 1.16 (0.85 – 1.59)
Cervical length 0.70
   < 15 mm 13/25 (52.0) 17/ 31(54.8) 0.95 (0.58 – 1.55)
   ≥15 mm 69/302 (22.8) 63/299 (21.1) 1.08 (0.80 – 1.47)
Cervical funnel 0.08
   Absent 54/239 (22.6) 50/261 (19.2) 1.18 (0.84 – 1.66)
   Present 28/88 (31.8) 30/69 (43.5) 0.73 (0.49 – 1.10)
*
Data presented as n/N (%)
**
P value for Breslow-Day interaction term
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Table 5





RR (95% CI) P**
Preterm birth < 37 weeks
   Cervical length 0.59
     < 10 mm 5/9 (55.6) 10/16 (62.5) 0.89 (0.44 – 1.78)
     10–20 mm 19/50 (38.0) 18/40 (45.0) 0.84 (0.52 – 1.38)
     > 20 mm 58/268 (21.6) 52/274 (19.0) 1.14 (0.82 – 1.59)
Preterm birth < 34 weeks
   Cervical length 0·82
     < 15 mm 9/25 (36·0) 13/31(41.9) 0·86 (0·44–1·67)
     ≥15 mm 32/302 (10.6) 35/299 (11.7) 0.91 (0·58–1·42)
   Cervical length 0·49
     < 10 mm 5/9 (55·6) 6/16 (37·5) 1.48 (0·63–3.51)
     10–20 mm 11/50 (22·0) 12/40 (30·0) 0·73 (0·36–1·48)
     > 20 mm 25/268 (9.3) 30/274 (10.9) 0·85 (0·52–1·41)
*
Data presented as n/N (%)
**
P value for Breslow-Day interaction term
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